The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations

ObjectiveTo explore the efficacy and safety of EGFR-TKI combined with thymosin therapy in advanced non-small cell lung cancer (NSCLC) patients harboring active EGFR mutations.MethodsPatients confirmed as advanced NSCLC with active EGFR mutations were recruited from August 2008 to July 2018 retrospec...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yongdong Feng, Guangkuo Zhu, Song Lang, Ping Hao, Guanghui Li, Fanglin Chen, Wenlei Zhuo, Yuzhong Duan, Anmei Zhang, Zhengtang Chen, Jianguo Sun
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2021-05-01
Col·lecció:	Frontiers in Oncology
Matèries:	NSCLC EGFR-TKI thymosin active EGFR mutations efficacy safety
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2021.659065/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!